For Our Patients
Clinical Trials and Research
Enrolling in
a Study
Interested in Enrolling?
Thank you for your interest in participating in one of our clinical trials. These studies offer eligible new patients the opportunity to receive the latest, most advanced treatments for vitreoretinal conditions — all under the expert care of our dedicated clinical research team.
Currently Enrolling Studies
Last updated on Monday, June 29, 2026
If you’re a new patient and would like to be considered for enrollment, please click Enroll in this Study to send us an email. Be sure to include: Your full name, the reason you're interested in participating, the office location where you currently receive treatment. Our team will respond within 48–72 hours.
Below is a list of studies currently open for enrollment:
RESEARCH LOCATION: ORLANDO
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration
Protocol ID: MK-8748-003 (TORRONTES)
ClinicalTrials.gov ID: NCT05769153
Sponsor: EyeBiotech Limited
TThis Phase 2/3 randomized, double-masked, multicenter clinical trial evaluates the safety and effectiveness of EYE201/MK-8748 (tiespectus) compared with aflibercept for the treatment of neovascular age-related macular degeneration (nAMD). The study aims to determine whether EYE201/MK-8748 can safely provide vision outcomes comparable to aflibercept in patients with nAMD.
Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Protocol ID: ONL1204-GA-002 (Galaxy)
ClinicalTrials.gov ID: NCT06659445
Sponsor: ONL Therapeutics
This Phase 2 randomized, double-masked, sham-controlled, multicenter clinical trial evaluates the safety and effectiveness of ONL1204 compared with sham treatment and avacincaptad pegol in patients with geographic atrophy (GA) associated with age-related macular degeneration (AMD). The study aims to evaluate whether ONL1204 can safely slow the progression of GA while preserving retinal cells and vision.
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (SIENNA)
Protocol ID: R3918-AMD-2326 (SIENNA)
ClinicalTrials.gov ID: NCT06541704
Sponsor: Regeneron Pharmaceuticals
This Phase 3 randomized, double-masked, placebo-controlled, multicenter clinical trial evaluates the safety, efficacy, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone compared with placebo in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study aims to determine whether these investigational treatments can safely slow the progression of geographic atrophy associated with AMD.
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Protocol ID: M24-528 (ACHIEVE)
ClinicalTrials.gov ID: NCT07007065
Sponsor: AbbVie
This Phase 3 randomized, controlled, partially masked, multicenter clinical trial evaluates the safety, efficacy, and long-term preservation of visual acuity of surabgene lomparvovec (ABBV-RGX-314) compared with ranibizumab in adults with previously treated neovascular age-related macular degeneration (nAMD). The study aims to determine whether this investigational gene therapy can maintain vision while reducing the treatment burden associated with frequent anti-VEGF injections.
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration (Phase III)
Protocol ID: 4D-150-C004 (4FRONT-2)
ClinicalTrials.gov ID: NCT07104812
Sponsor: 4D Molecular Therapeutics
This Phase 3 randomized, double-masked, active-controlled, multicenter clinical trial evaluates the safety, efficacy, and durability of a single intravitreal injection of 4D-150 compared with aflibercept in adults with neovascular age-related macular degeneration (nAMD). The study aims to determine whether a one-time administration of 4D-150 can provide vision outcomes comparable to standard anti-VEGF therapy while reducing the need for ongoing intravitreal injections.
A Phase 2, Randomized, Placebo-Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination With Syfovre® (Pegcetacoplan) in Patients Diagnosed With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Protocol ID: APL3007-GA-201 (GALLOP)
ClinicalTrials.gov ID: NCT07215390
Sponsor: Apellis Pharmaceuticals, Inc.
This Phase 2 randomized, placebo-controlled, multicenter, masked clinical trial evaluates the safety, efficacy, tolerability, and pharmacodynamics of multidose APL-3007 in combination with Syfovre® (pegcetacoplan) compared with Syfovre® alone in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study aims to determine whether the addition of APL-3007 can further slow the progression of geographic atrophy while maintaining an acceptable safety profile.
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
Protocol ID: ADX-038-202
ClinicalTrials.gov ID: NCT06990269
Sponsor: ADARx Pharmaceuticals, Inc.
This Phase 2 randomized, masked, placebo-controlled, multicenter clinical trial evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneously administered ADX-038 compared with placebo in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study aims to determine whether ADX-038 can safely slow the progression of geographic atrophy associated with AMD.
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Protocol ID: ADVM-022-13 (AQUARIUS)2
ClinicalTrials.gov ID: NCT07482176
Sponsor: Adverum Biotechnologies, Inc.
This Phase 3 randomized, double-masked, active-comparator-controlled, multicenter clinical trial evaluates the safety, efficacy, and tolerability of a single intravitreal injection of ixoberogene soroparvovec (Ixo-vec) compared with aflibercept in participants with neovascular age-related macular degeneration (nAMD). The study aims to determine whether Ixo-vec can provide vision outcomes comparable to standard anti-VEGF therapy with a single treatment while evaluating its long-term safety and durability.
RESEARCH LOCATION: JACKSONVILLE
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
Protocol ID: VX01-DR-201
ClinicalTrials.gov ID: NCT06770933
Sponsor: Vantage Biosciences Ltd.
This Phase 2 randomized, double-masked, placebo-controlled, multicenter clinical trial evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of orally administered VX-01 compared with placebo in participants with moderate to severe non-proliferative diabetic retinopathy (NPDR) without center-involved diabetic macular edema (CI-DME). The study aims to determine whether daily oral VX-01 can safely slow disease progression and help preserve vision in patients with NPDR.
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD) (NOVA-1)
Protocol ID: NCT05769153
ClinicalTrials.gov ID: NCT05769153
Sponsor: Alcon Research
This Phase 1/2 two-stage, randomized, multicenter clinical trial evaluates the safety, preliminary treatment effects, and durability of the AR-14034 sustained-release (SR) implant compared with intravitreal aflibercept in participants with neovascular age-related macular degeneration (nAMD). The study aims to determine whether AR-14034 SR can safely maintain vision while providing a durable treatment option for patients with nAMD.
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Protocol ID: R3918-AMD-2326 (SIENNA)
ClinicalTrials.gov ID: NCT06541704
Sponsor: Regeneron Pharmaceuticals
TThis Phase 3 randomized, double-masked, placebo-controlled, multicenter clinical trial evaluates the safety, efficacy, and tolerability of subcutaneously administered pozelimab in combination with cemdisiran or cemdisiran alone compared with placebo in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study aims to determine whether these investigational treatments can safely slow the progression of geographic atrophy associated with AMD.
RESEARCH LOCATION: WILDWOOD
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Protocol ID: ADX-038-202
ClinicalTrials.gov ID: NCT06990269
Sponsor: ADARx Pharmaceuticals
This Phase 2 randomized, masked, placebo-controlled study evaluates the efficacy, safety, pharmacokinetics, and pharmacodynamics of subcutaneously administered ADX-038, an investigational siRNA therapy, in patients with geographic atrophy secondary to age-related macular degeneration. The study is designed to assess whether systemic inhibition of complement factor B may slow the progression of GA lesions compared
to placebo, with the goal of addressing an unmet need in GA treatment
through a less invasive dosing approach than intravitreal therapies.
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002
Protocol ID: MK8748-002 (MALBEC)
ClinicalTrials.gov ID: NCT07440225
Sponsor: EyeBiotech Ltd.
This Phase 2/3 randomized, double-masked, multicenter clinical trial evaluates the safety and efficacy of intravitreal EYE201/MK-8748 (tiespectus) compared with aflibercept in participants with neovascular age-related macular degeneration (nAMD). The study aims to determine whether EYE201/MK-8748 is as effective as aflibercept in improving and maintaining vision while evaluating its safety profile.
Upcoming Studies
RESEARCH LOCATION: ORLANDO
To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors RTE888-E001 (NOVA-1)Sponsor: Alcon Research
This Phase 1/2 randomized, multicenter clinical trial evaluates the safety, preliminary effectiveness, and durability of the AR-14034 sustained-release (SR) implant compared with intravitreal aflibercept in participants with neovascular age-related macular degeneration (nAMD). The study aims to determine whether AR-14034 SR can safely provide durable treatment while maintaining vision.
RESEARCH LOCATION: WILDWOOD
A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are Tolerated 1523-0001 (Mallow)Sponsor: Boehringer Ingelheim
This Phase 1/2a first-in-human clinical trial evaluates the safety, tolerability, and appropriate dosing of BI 3812465 in participants with center-involved diabetic macular edema (DME). The study aims to determine the optimal dose while evaluating the treatment's safety profile.
STL303-202 (SITALA)
Sponsor: Sitala Bio
This Phase 2 randomized, sham-controlled clinical trial evaluates the safety and efficacy of STL-303 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The study aims to determine whether STL-303 can safely slow the progression of geographic atrophy while preserving retinal function.
OTX-TKI-2025-NPDR-302 (HELIOS 3)
Sponsor: Ocular Therapeutics
This Phase 3 randomized, masked, multicenter clinical trial evaluates the safety and efficacy of OTX-TKI, an investigational sustained-release axitinib implant, in participants with non-proliferative diabetic retinopathy (NPDR). The study aims to determine whether OTX-TKI can safely improve diabetic retinopathy severity and reduce disease progression.
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026 BGE-102-004
Sponsor: BioAge Labs
This Phase 1b/2a randomized, controlled clinical trial evaluates the safety, pharmacodynamics, and preliminary efficacy of oral BGE-102 in participants with diabetic macular edema (DME). The study aims to determine whether BGE-102 can reduce retinal inflammation and improve clinical outcomes in patients with DME.
MK-8748-004
Sponsor: Merck
This Phase 2/3 randomized, double-masked, multicenter clinical trial evaluates the safety and efficacy of EYE201/MK-8748 (tiespectus) in participants with diabetic macular edema (DME). The study aims to determine whether EYE201/MK-8748 can safely improve vision and retinal outcomes compared with standard anti-VEGF therapy.
Studies closed for Enrollment
For more information about clinical trials or if you should have any questions, please feel free to contact us.
